Volume 20, Number 6—June 2014
Short-Term Malaria Reduction by Single-Dose Azithromycin during Mass Drug Administration for Trachoma, Tanzania
|Variable||MDA treatment group||MDA control group|
|Bednet ownership, yes/no†||457/725 (63)||328/789 (42)|
|History of fever, yes/no†||26/813 (3)||10/869 (1)|
|Malaria medication, yes/no||157/814 (19)||161/869 (19)|
|Latrine access, yes/no||297/981 (30)||276/971 (28)|
|Education of head of household, yes/no||4.2 (3.41)||3.2 (3.46)|
|Altitude, m||1,206 (32.89)||1,200 (45.99)|
*Values are no. positive/no. tested (%) for categorical measures or mean (SD) for continuous measures. MDA, mass drug administration.
†p<0.05 by χ2 test.
1Current affiliation: Pfizer, Inc., New York, New York, USA.
Page created: May 16, 2014
Page updated: May 16, 2014
Page reviewed: May 16, 2014
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.